Latest Feature

Kimberly-Clark readies Halyard Health medical device spinout

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells MassDevice.com.

HART CEO David Green on the transformative potential for regenerative medicine

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

Podcast: Medtech legends and leaders on the state of medical device innovation

MassDevice.com brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

CardioMEMS took 11 years to pay off, but for Boston Millennia it was worth it

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Medtronic settles CRM kickbacks case with final, $362k payment

September 19, 2014 by Brad Perriello

Medtronic makes the final payment in the $11.1 million settlement of allegations that it ran a kickbacks scheme to influence sales of its cardiac rhythm management products, but admits no wrongdoing.

Medtronic settles CRM kickbacks case with final, $362k payment

House passes bill to repeal, refund medical device tax

September 19, 2014 by Brad Perriello

The U.S. House of Representatives passes a jobs package that would repeal the medical device tax and issue refunds for all levies paid since the 2.3% excise tax went into effect last year.

House passes bill to repeal, refund medical device tax

UPDATED Sept. 19, 2014, with comment from MDMA, MITA and AdvaMed. 

The U.S. House of Representatives voted yesterday to repeal and refund the medical device tax and promptly went into recess until after the mid-term elections in November.

Medigus secures $5.6M in funding, reveals positive outcomes from study of its MUSE surgical endostapling device | Medtech funding for the week of September 15, 2014

September 19, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Medigus raises $5.6M, touts clinical results for acid reflux device; Funding: InSightec raises $12.5M from Chinese backers; Corindus raises $26.6M for vascular robot; Intrinsic Therapeutics raises $17.2M for spinal surgery devices

Medigus raises $5.6M, touts clinical results for acid reflux device

September 12, 2014 by Arezu Sarvestani

Medigus raises $5.6M, touts clinical results for acid reflux device

Did Boston Scientific lose $74M mesh trial over an email? | MassDevice.com On Call

September 19, 2014 by Arezu Sarvestani

The most recent Boston Scientific mesh lawsuit, which cost the company $74 million, featured an internal email that may have made a major impact on the jury.

MassDevice.com On Call

MASSDEVICE ON CALL — Medtech titan Boston Scientific's (NYSE:BSX) logged a major loss after winning a few rounds in the ongoing lawsuits over its vaginal sling implants, and the deciding factor may have been the revelation of an internal company email.

Intersect ENT study aims to bring sinus implants to more patients

September 19, 2014 by Arezu Sarvestani

Intersect ENT enrolls the 1st patient in its PROGRESS study, aiming to expand the patient population for its steroid-eluting sinus implants.

Intersect ENT study aims to bring sinus implants to more patients

California device maker Intersect ENT (NSDQ:XENT) announced this week that it enrolled the 1st patient in its PROGRESS clinical trial, evaluating the company's Propel Mini sinus implant for treatment of frontal sinusitis.

Press Release: NxStage announces FDA clearance of Single Needle Technology

September 18, 2014 by MassDevice

Innovative needle design to enhance patient safety.

Press Release: NxStage announces FDA clearance of Single Needle Technology

LAWRENCE, Mass. -- 

NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced its single needle technology, OneSite, has received FDA clearance.

NxStage Medical's single-needle home dialysis system comes to the U.S.

September 18, 2014 by Arezu Sarvestani

NxStage Medical wins FDA clearance to market its OneSite single needle dialysis technology for use with its portable systems.

NxStage Medical's single-needle home dialysis system comes to the U.S.

Massachusetts-based dialysis devices maker NxStage Medical (NSDQ:NXTM) won FDA clearance for its OneSite technology, cutting down on the number of needles dialysis patients must endure during therapy.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp